Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is a rapidly growing medical technology company that is delivering personalized solutions for spine surgery through its FDA-cleared Aprevo technology platform. By providing customized pre-operative planning and implants, Carlsmed is able to improve clinical outcomes for patients undergoing spine fusion procedures. Additionally, the company has secured robust reimbursement from third-party payers, which sets it apart from traditional spine surgery. Carlsmed's focus on innovation and integration in the spine surgery market bodes well for its long-term growth potential.

Bears say

Carlsmed is a commercial-stage company operating in a highly competitive market with a concentrated customer base and facing reimbursement risks. While the company's entrance into the cervical spine market presents a significant opportunity, there are still uncertainties around utilization and adoption among existing customers, leading to a negative outlook on the stock.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.